To better understand the development of T1D in the setting of combination anti-PD-1 and anti-CTLA-4 antibody therapy, we conducted a genetic risk analysis of this patient based on single nucleotide polymorphism (SNP) and HLA risk allele sequencing. This evidence concerns the gene CTLA4 and type 1 diabetes mellitus.